KAHN BROTHERS GROUP INC

The most decisive Q/Q move is MBIA (MBI), the monoline bond insurer that was central to the 2008 financial crisis and has spent the subsequent 18 years running off legacy exposure while rebuilding its balance sheet. The position grew from $7.4 million to $12.2 million — a 100-percent increase in absolute dollars inside a single quarter. That is a meaningful conviction escalation for a $564 million book, and it is the most explicit special-situations call in the filing. The manager is not buying MBIA as a general financials bet; it is buying a name with a defined legacy tail risk and a shrinking book of new business whose run-off economics may be more valuable than the market currently discounts. Around the same time, Assured Guaranty — the better-capitalized, better-franchised peer — was sold. That is a deliberate choice to concentrate the monoline-insurance sleeve inside one name rather than hold both, and it suggests Kahn views MBIA's specific setup as offering better risk-reward than the sector as a whole.

The second-most decisive move is Merck's 47% cut from $45 million to $27 million. Merck had been the fourth-largest position at year-end, sitting just behind Disney and ahead of Alphabet. Reducing it by nearly half while simultaneously increasing Organon (OGN) from $26 million to $33 million reads as an explicit within-sector rotation: out of a legacy pharmaceutical company facing patent cliffs and pipeline disappointment, into a newer-generation women's-health spinoff that sits in a narrower therapeutic segment. Both are healthcare names, so the sector allocation looks stable at the surface, but the manager is clearly distinguishing between pharma businesses that have secular growth optionality and those that do not.